AHL Partners’s Meridian Bioscience Inc VIVO Stock Holding History

AHL Partners’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-34,361	Closed	-$491K	–	1401
2017 Q3	$491K	Sell	34,361 -23,054	-40%	-$329K	0.01%	1058
2017 Q2	$904K	Sell	57,415 -6,373	-10%	-$91.8K	0.02%	798
2017 Q1	$880K	Buy	+63,788	New	+$892K	0.02%	812
2016 Q4	–	Sell	-18,922	Closed	-$365K	–	1221
2016 Q3	$365K	Buy	18,922 +5,913	+45%	+$116K	0.01%	921
2016 Q2	$254K	Buy	+13,009	New	+$255K	0.01%	734

Other funds holding VIVO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return

Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

AHL Partners's VIVO Position: Q4 2017 in Review

AHL Partners sold out of Meridian Bioscience Inc (VIVO) in Q4 2017, closing a stake of 34,361 shares — an estimated $491K sold.

AHL Partners first reported a position in VIVO in Q2 2016 and held it in 5 quarters. The position peaked at $904K in Q2 2017. 178 funds tracked by Wall St. Rank hold VIVO as of Q4 2017.

AHL Partners reported no remaining Meridian Bioscience Inc position as of Q4 2017 after selling out during the quarter.
AHL Partners sold 34,361 Meridian Bioscience Inc shares in Q4 2017, an estimated $491K.
AHL Partners first reported a position in Meridian Bioscience Inc in Q2 2016 and held it in 5 quarters.
AHL Partners's Meridian Bioscience Inc position peaked at $904K in Q2 2017.
178 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q4 2017.

Based on AHL Partners's 13F filing for Q4 2017, filed 14 Feb 2018.